Drug updated on 3/28/2024
| Dosage Form | Injection (intravenous; 300 mg, 400 mg) |
| Drug Class | SLAMF7-directed immunostimulatory antibodies |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.
- In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Summary
- Elotuzumab (Empliciti) is used in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.
- It is also combined with pomalidomide and dexamethasone for treating adult patients with multiple myeloma who have undergone at least two previous treatments including lenalidomide and a proteasome inhibitor.
- Two systematic reviews/meta-analyses were reviewed, providing insights into the effectiveness of elotuzumab (Empliciti) when compared to other drug regimens in treating multiple myeloma.
- In a network meta-analysis involving 123 randomized controlled trials, triplet therapy containing monoclonal antibodies like elotuzumab was found superior for lenalidomide-refractory multiple myeloma; specifically, elotuzumab/pomalidomide/dexamethasone had higher efficacy than just using dexamethasone alone.
- Another Bayesian network meta-analysis indicated that daratumumab/lenalidomide/dexamethasone showed clear advantages over other IMiD-containing regimens such as carfilzomib/lenaldiomde/dexmethsane or ixazamib/lenaldiomde/dexmethsane; however, it did not specify how Empliciti performed relative to these combinations.
- The results from both analyses suggest that while Empliciti can be effective in certain combinations against refractory MM cases, more research may be needed to ascertain its optimal use among different patient subgroups and against various competing drug regimens.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Empliciti (elotuzumab) Prescribing Information. | 2022 | Bristol-Myers Squibb Company, Princeton, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| A systematic review and network meta-analysis of randomized data on efficacy of novel therapy combinations in patients with lenalidomide-refractory multiple myeloma. | 2021 | Clinical Lymphoma, Myeloma & Leukemia |
| A comparison of the efficacy of immunomodulatory-containing regimens in relapsed/refractory multiple myeloma: a network meta-analysis. | 2018 | Clinical Lymphoma, Myeloma & Leukemia |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. | 2019 | Journal of Clinical Oncology |